natgillin/translations-raw huggingface dataset:
Exforge HCT bruges til at behandle forhøjet blodtryk hos voksne patienter, hvis blodtryk allerede er kontrolleret med amlodipin, valsartan og hydrochlorthiazid, og som kan drage fordel af at tage én tablet, som indeholder alle tre stoffer. 
Exforge HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.
Exforge HCT enkelte komponenter 
Exforge HCT individual component
Der er ingen erfaring med overdosering af Exforge HCT. 
There is no experience of overdose with Exforge HCT.
Hos patienter, der tager Exforge HCT, og som får bivirkninger som svimmelhed, hovedpine, træthed eller kvalme, kan reaktionsevnen blive påvirket. 
If patients taking Exforge HCT suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired.
Exforge HCT tabletter indeholder tre stoffer, som kaldes amlodipin, valsartan og hydrochlorthiazid. 
Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide.
Hvis du ønsker at amme, kan din læge vælge en anden behandling til dig, især hvis dit barn er nyfødt eller født for tidligt. 
Exforge HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.
Amlodipin-komponenten i Exforge HCT hæmmer den transmembranale indstrømning af calciumioner i hjertets og karvæggens glatte muskulatur. 
The amlodipine component of Exforge HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle.
Sikkerheden af Exforge HCT er blevet vurderet ved den maksimale dosis på 10 mg/320 mg/25 mg i et kontrolleret, kortvarigt (8 uger) klinisk studie med 2.271 patienter, af hvilke 582 fik valsartan i kombination med amlodipin og hydrochlorthiazid. 
The safety of Exforge HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide.
Dosisjustering er ikke nødvendig hos patienter med let til moderat nedsat nyrefunktion (GFR ≥30 ml/min/1,73 m 
No dose adjustment of Exforge HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m
Exforge HCT tidligt i graviditeten - se afsnittet om Graviditet). 
(It is also recommended to avoid Exforge HCT in early pregnancy - see Pregnancy section.)
Exforge HCT kombinerer tre antihypertensive stoffer, som kontrollerer blodtrykket hos patienter med essentiel hypertension ved komplementære virkningsmekanismer: amlodipin tilhører klassen kaldet calciumantagonister, valsartan tilhører klassen kaldet angiotensin II-antagonister og hydrochlorthiazid tilhører klassen kaldet thiazid-diuretika. 
Exforge HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines.
- hvis du bliver svimmel og/eller besvimer under behandlingen med Exforge HCT, skal du fortælle det til din læge med det samme. 
if you experience dizziness and/or fainting during treatment with Exforge HCT, tell your doctor as soon as possible.
- hvis du har eller har haft hjertevigt eller sygdom i kranspulsåren, specielt hvis du får ordineret den højeste dosis af Exforge HCT (10 mg/320 mg/25 mg). 
if you have or have had heart failure or coronary artery disease, particularly if you are prescribed the maximum dose of Exforge HCT (10 mg/320 mg/25 mg).
Hvis der forekommer udtalt hypotension med Exforge HCT, skal patienten placeres i liggende rygstilling, og om nødvendigt skal der gives intravenøs infusion af isotonisk natriumchlorid. 
If excessive hypotension occurs with Exforge HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline.
Den maksimalt anbefalede dosis af Exforge HCT er 10 mg/320 mg/25 mg. 
The maximum recommended dose of Exforge HCT is 10 mg/320 mg/25 mg.
Når Exforge HCT anvendes hos patienter med nedsat nyrefunktion, anbefales regelmæssig monitorering af serumelektrolytter herunder kalium, samt serum-kreatinin og serum-urinsyre. 
When Exforge HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended.
Der er begrænset erfaring med brug af Exforge HCT til patienter med hjertesvigt og lidelser i kranspulsåren, især med den maksimale dosis. 
There is limited experience with the use of Exforge HCT, particulary at the maximum dose, in patients with heart failure and coronary artery disease.
Ændringerne i laboratorieværdier, som blev set i det kontrollerede kliniske studie af 8 ugers varighed, var små og i overensstemmelse med de farmakologiske virkningsmekanisme for komponenterne i monoterapi. 
In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Exforge HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents.
Hvis svær eller pludselig hyponatriæmi opstår under behandling med Exforge HCT, bør behandlingen seponeres, indtil natriumbalancen er normaliseret. 
In case severe or rapid hyponatraemia develops during Exforge HCT therapy, the treatment should be discontinued until normalisation of natraemia.
Der er ikke udført formelle interaktionsstudier af Exforge HCT i kombination med andre lægemidler. 
No formal interaction studies with other medicinal products have been performed with Exforge HCT.
Hvis hypokaliæmi opstår under behandling med hydrochlorthiazid, bør Exforge HCT seponeres, indtil kaliumbalancen er genoprettet og stabil. 
If hypokalaemia develops during hydrochlorothiazide therapy, Exforge HCT should be discontinued until stable correction of the potassium balance.
Følgende bivirkninger, som er opstillet efter systemorganklasser i henhold til MedDRA og hyppighed gælder for Exforge HCT (amlodipin/valsartan/hydrochlorthiazid) og amlodipin, valsartan og HCT individuelt. 
The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Exforge HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.
Behandling med Exforge HCT bør kun påbegyndes efter korrektion af hypokaliæmi og eventuel samtidig forekommende hypomagnesiæmi. 
Treatment with Exforge HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia.
Det skal du vide, før du begynder at tage Exforge HCT 
What you need to know before you take Exforge HCT
- hvis du samtidig tager et af følgende lægemidler til behandling af for højt blodtryk: en ACE-hæmmer (f.eks. enelapril, lisinopril, ramipril), især, hvis du har nyreproblemer i forbindelse med sukkersyge aliskiren. 
an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
Der er ikke udført fertilitetsstudier med Exforge HCT. 
There are no clinical studies on fertility with Exforge HCT.
Reduktionen i systolisk/diastolisk blodtryk med Exforge HCT var 7,6/5,0 mmHg større end med valsartan/hydrochlorthiazid; 6,2/3,3 mmHg større end med, amlodipin/valsartan og 8,2/5,3 mmHg større end med amlodipin/hydrochlorthiazid. 
The reductions in systolic/diastolic blood pressure with Exforge HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide.
De modsat rettede effekter af valsartan 320 mg og hydrochlorthiazid 25 mg på kaliumniveauet i serum balancerede næsten hinanden hos mange patienter i det kontrollerede studie. 
In the controlled trial of Exforge HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients.
Hvis du holder op med at tage Exforge HCT 
If you stop taking Exforge HCT
Hvis du har glemt at tage Exforge HCT 
If you forget to take Exforge HCT
I uge 8 var gennemsnitsreduktionen i systolisk/diastolisk blodtryk 39,7/24,7 mmHg med Exforge HCT; 32,0/19,7 mmHg med valsartan/hydrochlorthiazid; 33,5/21,5 mmHg med amlodipin/valsartan, og 31,5/19,5 mmHg med amlodipin/hydrochlorthiazid. 
At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Exforge HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide.
Det skyldes, at grapefrugt og grapefrugtjuice kan føre til en øget mængde af det aktive stof, amlodipin, i blodet. 
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Exforge HCT.
Exforge HCT bør kun bruges efter korrektion af eventuel eksisterende væske- eller natriummangel. 
Exforge HCT should be used only after correction of any pre-existing sodium and/or volume depletion.
Exforge HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter Exforge HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter Exforge HCT 5 mg/160 mg/25 mg filmovertrukne tabletter Exforge HCT 10 mg/160 mg/25 mg filmovertrukne tabletter Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter 
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Der skal udvises forsigtighed hos patienter med hjertesvigt og lidelser i kranspulsåren, især ved maksimumdosis af Exforge HCT, 10 mg/320 mg/25 mg. 
Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg.
Den maksimale anbefalede dosis til patienter med let til moderat nedsat leverfunktion uden kolestase er 80 mg valsartan, og Exforge HCT er derfor ikke egnet til denne patientgruppe (se pkt. 
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Exforge HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Hvis du ved et uheld har taget for mange Exforge HCT-tabletter, skal du straks kontakte en læge. 
If you take more Exforge HCT than you should If you have accidentally taken too many Exforge HCT tablets, talk to a doctor immediately.You may require medical attention.
Exforge HCT indeholder: 
What Exforge HCT contains
4.1) med nedsat leverfunktion skiftes til Exforge HCT, skal den laveste tilgængelige amlodipinkombination anvendes. 
When switching eligible elderly hypertensive patients (see section 4.1) to Exforge HCT, the lowest available dose of the amlodipine component should be used.
- Samtidig brug af Exforge HCT og lægemidler indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller nedsat nyrefunktion (GFR < 60 ml/min/1,73 m 2) (se pkt. 
Concomitant use of Exforge HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Tag ikke Exforge HCT - hvis du er mere end 3 måneder henne i graviditeten (det anbefales også at undgå brug af 
Do not take Exforge HCT if you are more than 3 months pregnant.
Der skal udvises forsigtighed, inklusive hyppigere monitorering af blodtrykket hos ældre patienter især ved den maksimale dosis af Exforge HCT, 10 mg/320 mg/25 mg, da der er begrænset tilgængelig data for denne patientpopulation. 
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.
I et kontrolleret studie af patienter med moderat til svær ukompliceret hypertension blev der set udtalt hypotension, inklusive ortostatisk hypotension hos 1,7 % af patienterne, som blev behandlet med den maksimale dosis af Exforge HCT (10 mg/320 mg/25 mg) sammenlignet med 1,8 % af patienterne, som blev behandlet med valsartan/hydrochlorthiazid (320 mg/25 mg), 0,4 % af patienterne, som blev behandlet med amlodipin/valsartan (10 mg/320 mg) og 0,2 % af patienterne, som blev behandlet med hydrochlorthiazid/amlodipin (25 mg/10 mg). 
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Exforge HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.
hydrochlorthiazid, sulfonamid-afledte stoffer (medicin, som bruges til at behandle infektioner i brystet eller urinvejene), eller et af de øvrige indholdsstoffer i Exforge HCT (angivet i punkt 6). 
if you are allergic to amlodipine or to any other calcium channel blockers, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of this medicine (listed in section 6).
Exforge HCT er kontraindiceret hos patienter med svært nedsat nyrefunktion, patienter med anuri og patienter i dialyse (se pkt. 
Exforge HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).
Exforge HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter Exforge HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter Exforge HCT 5 mg/160 mg/25 mg filmovertrukne tabletter Exforge HCT 10 mg/160 mg/25 mg filmovertrukne tabletter Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid 
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Der skal udvises forsigtighed over for patienter med hjertesvigt og lidelser i kranspulsåren, især ved den maksimale dosis af Exforge HCT, 10 mg/320 mg/25 mg, da der kun er begrænsede data tilgængelige fra disse patientgrupper. 
Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.
Dette er en sygdom, hvor dine binyrer producerer for meget af hormonet aldosteron. 
This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Exforge HCT is not recommended.
Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter 
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Pga. indholdet af valsartan er Exforge HCT kontraindiceret til patienter med stærkt nedsat leverfunktion (se pkt. 
Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
Brug af Exforge HCT sammen med mad, drikke og alkohol Du må ikke indtage grapefrugt og grapefrugtjuice, mens du får ordineret Exforge HCT. 
Grapefruit and grapefruit juice should not be consumed by people who are prescribed Exforge HCT.
Brug af Exforge HCT frarådes under amning. 
The use of Exforge HCT during breastfeeding is not recommended.
Brug af anden medicin sammen med Exforge HCT Fortæl altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Sådan skal du tage Exforge HCT 
How to take Exforge HCT
Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter er brun-gule, ovale tabletter præget med ”NVR” på den ene side og ”VFL” på den anden side. 
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Exforge HCT 5 mg/160 mg/25 mg filmovertrukne tabletter er gule, ovale tabletter præget med ”NVR” på den ene side og ”VEL” på den anden side. 
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
EU/1/09/569/007 280 filmovertrukne tabletter 
EU/1/09/569/007 280 film-coated tablets
Der kan opstå symptomatisk hypotension efter indledning af behandling med Exforge HCT hos patienter med væske- og/eller natriummangel, som fx patienter, der får høje doser diuretika. 
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Exforge HCT.
Exforge HCT 5 mg/160 mg/25 mg filmovertrukne tabletter 
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/160 mg/25 mg filmovertrukne tabletter 
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
EU/1/09/569/042 98 filmovertrukne tabletter 
EU/1/09/569/042 98 film-coated tablets
EU/1/09/569/001 14 filmovertrukne tabletter 
EU/1/09/569/001 14 film-coated tablets
EU/1/09/569/004 56 filmovertrukne tabletter 
EU/1/09/569/004 56 film-coated tablets
Exforge HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter 
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
EU/1/09/569/006 98 filmovertrukne tabletter 
EU/1/09/569/006 98 film-coated tablets
EU/1/09/569/043 280 filmovertrukne tabletter 
EU/1/09/569/043 280 film-coated tablets
EU/1/09/569/027 30 filmovertrukne tabletter 
EU/1/09/569/027 30 film-coated tablets
Exforge HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter 
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
EU/1/09/569/018 98 filmovertrukne tabletter 
EU/1/09/569/018 98 film-coated tablets
Exforge HCT 10 mg/160 mg/12,5 mg filmovertrukne tabletter er svagt gule, ovale tabletter præget med ”NVR” på den ene side og ”VDL” på den anden side. 
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter Aktive stoffer: amlodipin (som amlodipinbesylat), valsartan og hydrochlorthiazid. 
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
EU/1/09/569/005 90 filmovertrukne tabletter 
EU/1/09/569/005 90 film-coated tablets
EU/1/09/569/031 280 filmovertrukne tabletter 
EU/1/09/569/031 280 film-coated tablets
EU/1/09/569/041 90 filmovertrukne tabletter 
EU/1/09/569/041 90 film-coated tablets
EU/1/09/569/003 30 filmovertrukne tabletter 
EU/1/09/569/003 30 film-coated tablets
EU/1/09/569/030 98 filmovertrukne tabletter 
EU/1/09/569/030 98 film-coated tablets
EU/1/09/569/055 280 filmovertrukne tabletter 
EU/1/09/569/055 280 film-coated tablets
EU/1/09/569/019 280 filmovertrukne tabletter 
EU/1/09/569/019 280 film-coated tablets
EU/1/09/569/016 56 filmovertrukne tabletter 
EU/1/09/569/016 56 film-coated tablets
EU/1/09/569/054 98 filmovertrukne tabletter 
EU/1/09/569/054 98 film-coated tablets
EU/1/09/569/053 90 filmovertrukne tabletter 
EU/1/09/569/053 90 film-coated tablets
EU/1/09/569/025 14 filmovertrukne tabletter 
EU/1/09/569/025 14 film-coated tablets
EU/1/09/569/052 56 filmovertrukne tabletter 
EU/1/09/569/052 56 film-coated tablets
EU/1/09/569/040 56 filmovertrukne tabletter 
EU/1/09/569/040 56 film-coated tablets
EU/1/09/569/038 28 filmovertrukne tabletter 
EU/1/09/569/038 28 film-coated tablets
EU/1/09/569/029 90 filmovertrukne tabletter 
EU/1/09/569/029 90 film-coated tablets
EU/1/09/569/002 28 filmovertrukne tabletter 
EU/1/09/569/002 28 film-coated tablets
Exforge HCT 10 mg/320 mg/25 mg filmovertrukne tabletter amlodipin/valsartan/hydrochlorthiazid 
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
EU/1/09/569/049 14 filmovertrukne tabletter 
EU/1/09/569/049 14 film-coated tablets
EU/1/09/569/051 30 filmovertrukne tabletter 
EU/1/09/569/051 30 film-coated tablets
Det skal du vide, før du begynder at tage Exforge HCT Sådan skal du tage Exforge HCT Bivirkninger 
What Exforge HCT is and what it is used for What you need to know before you take Exforge HCT How to take Exforge HCT
Exforge HCT 10 mg/160 mg/25 mg filmovertrukne tabletter er brun-gule, ovale tabletter præget med ”NVR” på den ene side og ”VHL” på den anden side. 
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
EU/1/09/569/026 28 filmovertrukne tabletter 
EU/1/09/569/026 28 film-coated tablets
EU/1/09/569/017 90 filmovertrukne tabletter 
EU/1/09/569/017 90 film-coated tablets
EU/1/09/569/037 14 filmovertrukne tabletter 
EU/1/09/569/037 14 film-coated tablets
EU/1/09/569/039 30 filmovertrukne tabletter 
EU/1/09/569/039 30 film-coated tablets
Hvis du tror, du er overfølsom, skal du tale med din læge, inden du tager Exforge HCT. 
If you think you may be allergic, do not take Exforge HCT and talk to your doctor.
EU/1/09/569/013 14 filmovertrukne tabletter 
EU/1/09/569/013 14 film-coated tablets
EU/1/09/569/014 28 filmovertrukne tabletter 
EU/1/09/569/014 28 film-coated tablets
EU/1/09/569/028 56 filmovertrukne tabletter 
EU/1/09/569/028 56 film-coated tablets
EU/1/09/569/044 56 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/045 98 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/046 280 x 1 filmovertrukket tablet (enhedsdosis) 
EU/1/09/569/044 56 x 1 film-coated tablet (unit dose) EU/1/09/569/045 98 x 1 film-coated tablet (unit dose) EU/1/09/569/046 280 x 1 film-coated tablet (unit dose)
EU/1/09/569/050 28 filmovertrukne tabletter 
EU/1/09/569/050 28 film-coated tablets
EU/1/09/569/015 30 filmovertrukne tabletter 
EU/1/09/569/015 30 film-coated tablets
EU/1/09/569/056 56 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/057 98 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/058 280 x 1 filmovertrukket tablet (enhedsdosis) 
EU/1/09/569/056 56 x 1 film-coated tablet (unit dose) EU/1/09/569/057 98 x 1 film-coated tablet (unit dose) EU/1/09/569/058 280 x 1 film-coated tablet (unit dose)
EU/1/09/569/032 56 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/033 98 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/034 280 x 1 filmovertrukket tablet (enhedsdosis) 
EU/1/09/569/032 56 x 1 film-coated tablet (unit dose) EU/1/09/569/033 98 x 1 film-coated tablet (unit dose) EU/1/09/569/034 280 x 1 film-coated tablet (unit dose)
EU/1/09/569/008 56 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/009 98 x 1 filmovertrukket tablet (enhedsdosis) EU/1/09/569/010 280 x 1 filmovertrukket tablet (enhedsdosis) 
EU/1/09/569/008 56 x 1 film-coated tablet (unit dose) EU/1/09/569/009 98 x 1 film-coated tablet (unit dose) EU/1/09/569/010 280 x 1 film-coated tablet (unit dose)
Exforge HCT 5 mg/160 mg/25 mg filmovertrukne tabletter Aktive stoffer: amlodipin (som amlodipinbesylat), valsartan og hydrochlorthiazid. 
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
På grund af indholdet af valsartan er Exforge HCT kontraindiceret til patienter med nedsat leverfunktion (se pkt. 
Due to the valsartan component, Exforge HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).
Exforge HCT 5 mg/160 mg/12,5 mg filmovertrukne tabletter Aktive stoffer: amlodipin (som amlodipinbesylat), valsartan og hydrochlorthiazid. 
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.